Nebulized budesonide in the treatment of exacerbations of chronic obstructive pulmonary disease: Efficacy, safety, and effects on the serum levels of soluble differentiation molecules

Terapevticheskii Arkhiv

Volumn 88, Issue 3, 2016, Pages 24-31

  Makarova, E V ^a   Varvarina, G N ^a   Menkov, N V ^a   Czapaeva, M Yu ^b   Lazareva, E S ^c   Kazatskaya, Zh A ^c   Novikov, V V ^c   Karaulov, A V ^d  

^a PRIVOLZHSKY RESEARCH MEDICAL UNIVERSITY   (Russian Federation)

^b City Clinical Hospital   (Russian Federation)

^c LOBACHEVSKY STATE UNIVERSITY OF NIZHNY NOVGOROD   (Russian Federation)

^d I M SECHENOV FIRST MOSCOW STATE MEDICAL UNIVERSITY   (Russian Federation)

Author keywords

Exacerbation of chronic obstructive pulmonary disease; Glucocorticosteroids; Nebulized budesonide; Soluble differentiation molecules

Indexed keywords

BRONCHODILATING AGENT; BUDESONIDE; CORTICOSTEROID; LEUKOCYTE ANTIGEN; PREDNISOLONE;

ADULT; BLOOD; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EFFECTS; FEMALE; HUMAN; INHALATIONAL DRUG ADMINISTRATION; MALE; MIDDLE AGED; NEBULIZER; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RANDOMIZED CONTROLLED TRIAL;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; ADULT; ANTIGENS, CD; BRONCHODILATOR AGENTS; BUDESONIDE; FEMALE; HUMANS; MALE; MIDDLE AGED; NEBULIZERS AND VAPORIZERS; OUTCOME ASSESSMENT (HEALTH CARE); PREDNISOLONE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 84974679286     PISSN: 00403660     EISSN: None     Source Type: Journal    
DOI: 10.17116/terarkh201688324-31     Document Type: Article

References (26)

1. Chung K, Adcock I. Multifaceted mechanisms in COPD: inflammation, immunity, and tissue repair and destruction. Eur Respir J. 2008;31(6):1334-1356. doi:0.1183/09031936.00018908.
2. Lebedev MJ, Krizhanova MA, Vilkov SA et al. Peripheral blood lymphocytes immunophenotype and serum concentration of soluble HLA class I in burn patients. BURNS. 2003;29(2):123-128.
3. Lebedev MJ, Egorova NI, Sholkina MN et al. Serum levels of different forms of soluble CD38 antigen in burned patients. BURNS. 2004;30(6):552-556.
4. Novikov VV, Egorova NI, Kurnikov GYu et al. Serum levels of soluble HLA and IL-2R molecules in patients with urogenital Chlamydia infection. Immune-mediated diseases: from theory to therapy book series. Advances In Experl Medi Biol. 2007;601:285-289.
5. Rodrigo G. Rapid Effects of Inhaled Corticosteroids in Acute Asthma: an evidence-based evaluation. Chest. 2006;130(5):1301-1311. doi:10.1378/chest.130.5.1301.
6. Maltais F, Ostinelli J, Bourbeau J et al. Comparison of nebulized budesonide and oral prednisolone with placebo in the treatment of acute exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial. Am J Respir Crit Care Med. 2002;165(5):698-703. doi:10.1164/ajrccm.165.5.2109093.
7. Gunen H, Hacievliyagil SS, Yetkin O, Gulbas G, Mutlu GL, In E. The role of nebulised budesonide in the treatment of exacerbations of COPD. Eur Respir J. 2007;29(4):660-667. doi:10.1183/09031936.00073506.
8. Yilmazel Ucar E, Araz O, Meral M, Sonkaya E, Saglam L, Kaynar H, Gorguner AM, Akgun M. Two different dosages of nebulized steroid versus parenteral steroid in the management of COPD exacerbations: A randomized control trial. Med Sci Monit. 2014;20:513-520. doi:10.12659/msm.890210.
9. Sun X, He Z, Zhang J et al. Compare the efficacy of inhaled budesonide and systemic methylprednisolone on systemic inflammation of AECOPD. Pulmon Pharmacol Ther. 2015;31:111-116. doi:10.1016/j.pupt.2014.09.004.
10. Garnacho-Montero J, Olaechea P, Alvarez-Lerma F, Alvarez-Rocha L, Blanquer J, Galván B, Rodriguez A, Zaragoza R, Aguado JM, Mensa J, Solé A, Barberán J. Epidemiology, diagnosis and treatment of fungal respiratory infections in the critically ill patient. Rev Esp Quimioter. 2013;26(2):173-188.
11. Vogelmeier C. Systemic steroids in COPD-the beauty and the beast. Respir Res. 2014;15(1):38. doi:10.1186/1465-9921-15-38.
12. Kiser TH, Allen RR, Valuck RJ, Moss M, Vandivier RW. Outcomes associated with corticosteroid dosage in critically ill patients with acute exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2014;189(9):1052-1064. doi:10.1164/rccm.201401-0058OC
13. Walters JA, Tan DJ, White CJ, Gibson PG, Wood-Baker R, Walters EH. Systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2014;9:CD001288. doi:10.1002/14651858. CD001288.pub4.
14. Barnes P. Corticosteroid resistance in patients with asthma and chronic obstructive pulmonary disease. J Allergy Clin Immunol. 2013;131(3):636-645. doi:10.1016/j.jaci.2012.12.1564.
15. Sahid El-Radhi A, Hogg CL, Bungre JK, Bush A, Corrigan CJ. Effect of oral glucocorticoid treatment on serum inflammatory markers in acute asthma. Arch Dis Child. 2000;83(2):158-162.
16. Blidberg K, Palmberg L, James A et al. Adhesion molecules in subjects with COPD and healthy non-smokers: a cross sectional parallel group study. Respir Res. 2013;14(1):47. doi:10.1186/1465-9921-14-47.
17. Orciani M, Trubiani O, Guarnieri S, Ferrero E, Di Primio R. CD38 is constitutively expressed in the nucleus of human hematopoietic cells. J Cell Biochem. 2008;105(3):905-912. doi:10.1002/jcb.21887.
18. Gorska-Ciebiada M, Ciebiada M, Gorska M, Gorski P, Grzelewska-Rzymowska I. Intercellular adhesion molecule 1 and tumor necrosis factor a in asthma and persistent allergic rhinitis: relationship with disease severity. Ann Allergy, Asthma Immunol. 2006;97(1):66-72. doi:10.1016/s1081-1206 (10) 61372-5.
19. Tirumurugaan K, Kang B, Panettieri R, Foster D, Walseth T, Kannan M. Regulation of the cd38 promoter in human airway smooth muscle cells by TNF-α and dexamethasone. Respir Res. 2008;9(1):26. doi:10.1186/1465-9921-9-26.
20. Pang B, Hong W, West-Barnette SL, Kock ND, Swords WE. Diminished ICAM-1 expression and impaired pulmonary clearance of nontypeable Haemophilus influenzae in a mouse model of chronic obstructive pulmonary disease/emphysema. Infect Immun. 2008;76(11):4959-4967. doi:10.1128/IAI.00664-08.
21. 2-Adrenoceptor Agonist. J Asthma. 1998;35(5):401-408. doi:10.3109/02770909809048948.
22. Kanoh S, Rubin B. Mechanisms of Action and Clinical Application of Macrolides as Immunomodulatory Medications. Clin Microbiol Rev. 2010;23(3):590-615. doi:10.1128/cmr.00078-09.
23. Yamaya M, Nishimura H, Hatachi Y et al. Inhibitory effects of tiotropium on rhinovirus infection in human airway epithelial cells. Eur Respir J. 2012;40(1):122-132. doi:10.1183/09031936.00065111.
24. Yamaya M, Nishimura H, Nadine LK, Ota C, Kubo H, Nagatomi R. Ambroxol inhibits rhinovirus infection in primary cultures of human tracheal epithelial cells. Arch Pharm Res. 2014;37(4):520-529. doi:10.1007/s12272-013-0210-7.
25. Singh S, Loke Y. Risk of pneumonia associated with long-term use of inhaled corticosteroids in chronic obstructive pulmonary disease: a critical review and update. Cur Opin Pulmon Med. 2010;16(2):118-122. doi:10.1097/mcp. 0b013e328334c085.
26. Kew KM, Seniukovich A. Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2014;3:CD010115. doi:10.1002/14651858. CD010115.pub2.